Effect of pneumococcal conjugate vaccine on prevalence of otitis media with effusion among children in Vietnam
•Pneumococcal conjugate vaccine reduced otitis media with effusion in infants.•Otitis media with non-vaccine type was transiently increased in post-vaccine period.•Timely vaccination and higher herd immunity can increase the effect. Otitis media with effusion (OME) is common in young children and is...
Gespeichert in:
Veröffentlicht in: | Vaccine 2022-08, Vol.40 (36), p.5366-5375 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | •Pneumococcal conjugate vaccine reduced otitis media with effusion in infants.•Otitis media with non-vaccine type was transiently increased in post-vaccine period.•Timely vaccination and higher herd immunity can increase the effect.
Otitis media with effusion (OME) is common in young children and is associated with Streptococcus pneumoniae infection. We aimed to determine the impact of pneumococcal conjugate vaccine (PCV) introduction on the prevalence of OME and OME associated with vaccine-type (VT) or non-VT.
Population-based cross-sectional surveys were conducted in pre- (2016) and post-PCV periods (2017, 2018, and 2019) at selected communes in Nha Trang, Vietnam. For each survey, we randomly selected 60 children aged 4–11 months and 60 aged 14–23 months from each commune. Nasopharyngeal sample collection and tympanic membrane examination by digital otoscope were performed. S. pneumoniae was detected and serotyped by lytA qPCR and microarray. Odds ratios (OR) and 95% confidence intervals (CIs) were calculated using Firth’s logistic regression, stratified by age group.
Over the four surveys, 2089 children had a bilateral ear examination. Compared to pre-PCV, the prevalence of OME reduced in 2018 (OR 0.51, 95 %CI 0.28–0.93) and in 2019 (OR 0.53, 95 %CI 0.29–0.97) among the |
---|---|
ISSN: | 0264-410X 1873-2518 |
DOI: | 10.1016/j.vaccine.2022.07.047 |